| scholarly article | Q13442814 |
| P2093 | author name string | A B SABIN | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | World War II | Q362 |
| Dengue virus | Q476209 | ||
| war | Q198 | ||
| P304 | page(s) | 30-50 | |
| P577 | publication date | 1952-01-01 | |
| P1433 | published in | American Journal of Tropical Medicine and Hygiene | Q15766943 |
| P1476 | title | Research on dengue during World War II | |
| P478 | volume | 1 |
| Q66679555 | A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice |
| Q28595143 | A New Look at an Old Disease: Recent Insights into the Global Epidemiology of Dengue |
| Q96641970 | A Phase 1, Open Label- Assessment of a Dengue Virus-1 Live Virus Human Challenge - (DENV-1-LVHC) Strain |
| Q42976991 | A Reevaluation of the Role of Aedes albopictus in Dengue Transmission |
| Q94548612 | A Step in the Right Direction |
| Q43036625 | A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles |
| Q37012203 | A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection |
| Q28483765 | A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent mice |
| Q34235005 | A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein |
| Q38973106 | A laboratory and field evaluation of Macrocyclops distinctus, Megacyclops viridis and Mesocyclops pehpeiensis as control agents of the dengue vector Aedes albopictus in a peridomestic area in Nagasaki, Japan |
| Q24276108 | A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease |
| Q28744230 | A model framework to estimate impact and cost of genetics-based sterile insect methods for dengue vector control |
| Q38184218 | A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available |
| Q40134826 | A role for vector control in dengue vaccine programs |
| Q55385624 | A serologic study of dengue in northwest Ethiopia: Suggesting preventive and control measures. |
| Q40913845 | A serological survey on arbovirus antibodies in the Sudan |
| Q37443026 | A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand |
| Q36607295 | A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial |
| Q33988937 | A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial |
| Q59793336 | A study of clinical, hematological, and biochemical profiles of patients with dengue viral infections in Northwest Ethiopia: implications for patient management |
| Q40345843 | A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice |
| Q40281754 | A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice |
| Q27486967 | ARTHROPOD-BORNE VIRUS INFECTIONS OF ABORIGINES INDIGENOUS TO AUSTRALASIA. A PRELIMINARY REPORT |
| Q38157807 | Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue |
| Q35727211 | Activation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection |
| Q96438199 | Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design? |
| Q91212064 | Adaptive immune responses to primary and secondary dengue virus infections |
| Q27477784 | Advances in dengue diagnosis |
| Q27486475 | Aedes aegypti and haemorrhagic fever |
| Q40796985 | Aedes albopictus in North America: probable introduction in used tires from northern Asia |
| Q100429953 | Affinity-Restricted Memory B Cells Dominate Recall Responses to Heterologous Flaviviruses |
| Q33945431 | Age-specificity of clinical dengue during primary and secondary infections |
| Q35908172 | Alphavirus expression systems: applications to mosquito vector studies |
| Q40502077 | Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes |
| Q92872653 | An Innovative Prospective Hybrid Cohort-Cluster Study Design To Characterize Dengue Virus Transmission In Multigenerational Households In Kamphaeng Phet, Thailand |
| Q34261544 | An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952–1953 II. General description and epidemiology |
| Q24606493 | An in-depth analysis of original antigenic sin in dengue virus infection |
| Q41676281 | Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes |
| Q94523122 | Analysis of Serum Anti-Zika Virus Antibodies by Focus Reduction Neutralization Test |
| Q34999885 | Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases |
| Q37987131 | Animal models of dengue virus infection |
| Q38825543 | Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model |
| Q40380083 | Antibodies determine virulence in dengue |
| Q36931818 | Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo |
| Q27486409 | Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II |
| Q38240020 | Antibody response to dengue virus |
| Q60305271 | Antigenicity Determination and Clustering of Dengue Virus Serotypes |
| Q27469520 | Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses |
| Q34726048 | Arboviruses causing human disease in the Australasian zoogeographic region |
| Q34629302 | Are we modelling the correct dataset? Minimizing false predictions for dengue fever in Thailand |
| Q45711506 | Arthropod-borne virus diseases of man. |
| Q43046840 | Assessing Zika virus replication and the development of Zika-specific antibodies after a mid-gestation viral challenge in guinea pigs |
| Q38837531 | Assessing dengue vaccination impact: Model challenges and future directions |
| Q54206736 | Assessing the effects of daily commuting in two-patch dengue dynamics: a case study of Cali, Colombia. |
| Q28730914 | Assessing the potential of a candidate dengue vaccine with mathematical modeling |
| Q36487320 | Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients |
| Q40541509 | Atypical antibody responses in dengue vaccine recipients. |
| Q57091779 | Autochthonous spread of DENV-3 genotype III in Malaysia mitigated by pre-existing homotypic and heterotypic immunity |
| Q36950883 | B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts |
| Q37673123 | B cell response and mechanisms of antibody protection to West Nile virus |
| Q58701074 | B cell subset alteration and the expression of tissue homing molecules in dengue infected patients |
| Q33768932 | B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans |
| Q35567408 | B-cell responses during primary and secondary dengue virus infections in humans |
| Q40318253 | Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model |
| Q90707517 | Balanced immunity is key for a successful dengue vaccine |
| Q42991886 | Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis |
| Q59349637 | Basics of memory B-cell responses: lessons from and for the real world |
| Q26746185 | Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment |
| Q27480369 | Both Virus and Tumor Necrosis Factor Alpha Are Critical for Endothelium Damage in a Mouse Model of Dengue Virus-Induced Hemorrhage |
| Q37195614 | Breaking the symmetry: immune enhancement increases persistence of dengue viruses in the presence of asymmetric transmission rates |
| Q27469356 | Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones |
| Q35760439 | CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice |
| Q94595444 | COVID-19 vaccines: breaking record times to first-in-human trials |
| Q26825708 | Can non-human primates serve as models for investigating dengue disease pathogenesis? |
| Q45227328 | Cardiac involvement in Dengue Haemorrhagic Fever |
| Q24276104 | Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model |
| Q33399680 | Cells in dengue virus infection in vivo. |
| Q42981499 | Challenge accepted: Human challenge trials for dengue |
| Q35596803 | Challenge model for Helicobacter pylori infection in human volunteers |
| Q38121757 | Challenges for the formulation of a universal vaccine against dengue. |
| Q54238236 | Challenges in dengue research: A computational perspective. |
| Q27468886 | Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines |
| Q33402211 | Changes in hematological and serum biochemical parameters in common marmosets (Callithrix jacchus) after inoculation with dengue virus |
| Q39420042 | Changing pattern of dengue virus serotypes circulating during 2008-2012 and reappearance of dengue serotype 3 may cause outbreak in Kolkata, India. |
| Q27486788 | Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus |
| Q40441111 | Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus |
| Q40448371 | Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses. |
| Q96641974 | Characterization of the type-specific and cross-reactive B cell responses elicited by a live-attenuated tetravalent dengue vaccine |
| Q27469872 | Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice |
| Q34389377 | Chemically induced temperature-sensitive mutants of dengue virus type 2: comparison of temperature sensitivity in vitro with infectivity suckling mice, hamsters, and rhesus monkeys |
| Q28237906 | Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis |
| Q33208947 | Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses |
| Q41928393 | Chymase is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients |
| Q30577169 | Climate change, population immunity, and hyperendemicity in the transmission threshold of dengue |
| Q27490805 | Clinical Findings and Pro-Inflammatory Cytokines in Dengue Patients in Western India: A Facility-Based Study |
| Q39620105 | Clinical significance of skin rash in dengue fever: A focus on discomfort, complications, and disease outcome. |
| Q40333254 | Cocirculation of two dengue virus serotypes in individual and pooled samples of Aedes aegypti and Aedes albopictus larvae |
| Q27470062 | Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections |
| Q34450750 | Comparative expression profiles of midgut genes in dengue virus refractory and susceptible Aedes aegypti across critical period for virus infection |
| Q33943479 | Comparing dengue and chikungunya emergence and endemic transmission in A. aegypti and A. albopictus |
| Q56342856 | Comparing the effectiveness of different strains of Wolbachia for controlling chikungunya, dengue fever, and zika |
| Q37287595 | Comparison of the mosquito inoculation technique and quantitative real time polymerase chain reaction to measure dengue virus concentration |
| Q39535403 | Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development |
| Q35758626 | Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies |
| Q27485430 | Concurrent infections by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, India |
| Q40303387 | Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes |
| Q91807708 | Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention |
| Q40060246 | Construct and expression of recombinant domains I/II of dengue virus- 2 and its efficacy to evaluate immune response in endemic area: Possible use in prognosis |
| Q37625323 | Construction of intertypic chimeric dengue viruses by substitution of structural protein genes |
| Q27480293 | Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice |
| Q30361791 | Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland. |
| Q35251811 | Continuous dengue type 1 virus genotype shifts followed by co-circulation, clade shifts and subsequent disappearance in Surabaya, Indonesia, 2008-2013. |
| Q39307546 | Contrasting associations of polymorphisms in FcγRIIa and DC-SIGN with the clinical presentation of dengue infection in a Mexican population. |
| Q55119556 | Contributions from the silent majority dominate dengue virus transmission. |
| Q21562250 | Controlling dengue with vaccines in Thailand |
| Q38016235 | Controversies in dengue pathogenesis |
| Q37750121 | Correlates of protection induced by vaccination |
| Q34779065 | Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans |
| Q37907783 | Critical issues in dengue vaccine development |
| Q90345244 | Cross-Reactive Immunity Among Flaviviruses |
| Q36511979 | Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice |
| Q56341981 | Cross-reactive Dengue virus-specific CD8 T cells protect against Zika virus during pregnancy |
| Q34354665 | Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins |
| Q30393251 | Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus |
| Q93116456 | Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam |
| Q40995688 | Cultivation of mouse-passaged dengue viruses in human and animal tissue cultures |
| Q38130438 | Current issues in dengue vaccination |
| Q92106605 | Cutaneous Dengue Virus Inoculation Triggers Strong B Cell Reactions but Contrastingly Poor T Cell Responses |
| Q33676842 | DHIM supporting immunologic investigations and the identification of immune correlates of protection |
| Q36883189 | Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever |
| Q91711499 | Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade |
| Q33798068 | Delineating antibody recognition against Zika virus during natural infection |
| Q59349881 | Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine |
| Q29619772 | Dengue |
| Q56422387 | Dengue |
| Q38535918 | Dengue Antibody-Dependent Enhancement: Knowns and Unknowns |
| Q40133947 | Dengue Human Infection Models to Advance Dengue Vaccine Development |
| Q91688064 | Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice |
| Q92696785 | Dengue Outbreak during Ongoing Civil War, Taiz, Yemen |
| Q36745257 | Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection |
| Q46058515 | Dengue Viruses and Lifelong Immunity: Reevaluating the Conventional Wisdom |
| Q56766754 | Dengue and Dengue Hemorrhagic Fever |
| Q24736754 | Dengue and US military operations from the Spanish-American War through today |
| Q65000498 | Dengue and Zika Virus Diagnostic Testing for Patients with a Clinically Compatible Illness and Risk for Infection with Both Viruses. |
| Q24550739 | Dengue and dengue hemorrhagic fever |
| Q30414861 | Dengue and dengue-like outbreaks in the past: the case of the Macau epidemic fever of 1874. |
| Q35880707 | Dengue emergence and adaptation to peridomestic mosquitoes |
| Q38614539 | Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past. |
| Q35625026 | Dengue epidemiology: virus epidemiology, ecology, and emergence |
| Q40801046 | Dengue fever in India |
| Q30245613 | Dengue fever virus in Pakistan: effects of seasonal pattern and temperature change on distribution of vector and virus |
| Q40469197 | Dengue fever with hemorrhagic features in a special forces soldier. |
| Q83229772 | Dengue genetic divergence generates within-serotype antigenic variation, but serotypes dominate evolutionary dynamics |
| Q27477694 | Dengue haemorrhagic fever: a risk of returning home |
| Q33951512 | Dengue human infection model performance parameters |
| Q33724565 | Dengue human infection model: introduction |
| Q39521661 | Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development |
| Q38386336 | Dengue human infection models to advance dengue vaccine development |
| Q40700667 | Dengue in a urban locality of southeastern Brazil: epidemiological aspects |
| Q38122374 | Dengue in the United States of America: a worsening scenario? |
| Q42996339 | Dengue infection. |
| Q99575997 | Dengue mouse models for evaluating pathogenesis and countermeasures |
| Q35458940 | Dengue on islands: a Bayesian approach to understanding the global ecology of dengue viruses |
| Q51848076 | Dengue outbreak in a hilly state of Arunachal Pradesh in Northeast India. |
| Q39615846 | Dengue patients exhibit higher levels of PrM and E antibodies than their asymptomatic counterparts. |
| Q34042859 | Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection |
| Q37270826 | Dengue serotype immune-interactions and their consequences for vaccine impact predictions |
| Q40492701 | Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice |
| Q44163965 | Dengue transmission without involvement of mosquito vector |
| Q40589716 | Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine |
| Q27480386 | Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys |
| Q37608075 | Dengue vaccine candidates in development |
| Q42985743 | Dengue vaccine: hypotheses to understand CYD-TDV-induced protection |
| Q35964754 | Dengue vaccine: priorities and progress |
| Q34640032 | Dengue vaccines approach the finish line |
| Q40162746 | Dengue vaccines for travelers: has the time come? |
| Q38307813 | Dengue vaccines: challenges, development, current status and prospects |
| Q38655880 | Dengue vaccines: implications for dengue control |
| Q34367194 | Dengue vaccines: recent developments, ongoing challenges and current candidates |
| Q35183803 | Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcγ receptors |
| Q40536181 | Dengue vector prevalence and virus infection in a rural area in south India |
| Q34118200 | Dengue virus |
| Q98774861 | Dengue virus 4: the "black sheep" of the family? |
| Q34117580 | Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection |
| Q36286276 | Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus |
| Q40241412 | Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design |
| Q35659085 | Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice |
| Q34184747 | Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells |
| Q38158411 | Dengue virus infection: current concepts in immune mechanisms and lessons from murine models |
| Q39432395 | Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection |
| Q34351011 | Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies |
| Q39541495 | Dengue virus regulates type I interferon signalling in a strain-dependent manner in human cell lines |
| Q24737245 | Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus |
| Q38174307 | Dengue virus vaccine development |
| Q27491021 | Dengue virus-induced hemorrhage in a nonhuman primate model |
| Q36930903 | Dengue virus-mosquito interactions |
| Q40485716 | Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes |
| Q45324929 | Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge |
| Q27486068 | Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination |
| Q27485050 | Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody |
| Q54268496 | Dengue viruses and promising envelope protein domain III-based vaccines. |
| Q36926525 | Dengue viruses cluster antigenically but not as discrete serotypes |
| Q47438250 | Dengue viruses in Papua New Guinea: evidence of endemicity and phylogenetic variation, including the evolution of new genetic lineages |
| Q24737247 | Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century |
| Q35276730 | Dengue--quo tu et quo vadis? |
| Q33898170 | Dengue-2 vaccine: viremia and immune responses in rhesus monkeys |
| Q55109773 | Dengue-Virus-Infektionen |
| Q38922598 | Dengue: Lessons of an Outbreak |
| Q33624327 | Dengue: challenges for policy makers and vaccine developers |
| Q56793103 | Dengue: defining protective versus pathologic immunity |
| Q24609884 | Dengue: defining protective versus pathologic immunity |
| Q28729764 | Dengue: knowledge gaps, unmet needs, and research priorities |
| Q36641738 | Dengue: the syndromic basis to pathogenesis research. Inutility of the 2009 WHO case definition |
| Q27472847 | Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys |
| Q36427558 | Detection of dengue group viruses by fluorescence in situ hybridization |
| Q102206025 | Determining dengue virus serostatus by indirect IgG ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a prospective population-based study |
| Q38201151 | Developing a dengue vaccine: progress and future challenges |
| Q34184711 | Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization |
| Q35206695 | Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine |
| Q64125827 | Development of Dengue-type NS1 ELISA for Rapid Detection and Differentiation of Dengue Serotypes during Early Infection |
| Q36428460 | Development of a live attenuated dengue virus vaccine using reverse genetics |
| Q38609515 | Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward |
| Q38048849 | Diagnosis of dengue: an update |
| Q59349205 | Differences in Transmission and Disease Severity Between 2 Successive Waves of Chikungunya |
| Q27477546 | Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human Fc RIA (CD64) or Fc RIIA (CD32) |
| Q92019665 | Differential replicative fitness of the four dengue virus serotypes circulating in Colombia in human liver Huh7 cells |
| Q34408025 | Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus |
| Q33933986 | Diverse intracellular pathogens activate type III interferon expression from peroxisomes |
| Q39038294 | Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics? |
| Q40116225 | Domestic dengue epidemic in Japan, 2014. |
| Q35842365 | Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans |
| Q34472192 | Dynamic epidemiological models for dengue transmission: a systematic review of structural approaches |
| Q35895444 | Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity |
| Q35613335 | Dynamics of flavivirus infection in mosquitoes |
| Q47311278 | EDiP: the Epitope Dilution Phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens |
| Q40697798 | ELISA for detecting dengue and Japanese encephalitis viral antigen in mosquitoes |
| Q59356878 | Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers |
| Q40049012 | Early warning signal for dengue outbreaks and identification of high risk areas for dengue fever in Colombia using climate and non-climate datasets |
| Q27473480 | Ecological and immunological determinants of dengue epidemics |
| Q91913278 | Effective Dengue Vaccines: A Pipe Dream? |
| Q98286800 | Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus |
| Q34480475 | Eilat virus induces both homologous and heterologous interference |
| Q33430347 | Elevated levels of vascular endothelial growth factor in adults with severe dengue infection |
| Q60174613 | Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity |
| Q55064594 | Elimination of Falciparum Malaria and Emergence of Severe Dengue: An Independent or Interdependent Phenomenon? |
| Q35551855 | Emergence of a new lineage of dengue virus type 2 identified in travelers entering Western Australia from Indonesia, 2010-2012. |
| Q53689044 | Emergence of the Asian lineage dengue virus type 3 genotype III in Malaysia. |
| Q36756643 | Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity |
| Q27860800 | Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses |
| Q35625041 | Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis |
| Q40369297 | Epidemics with multistrain interactions: the interplay between cross immunity and antibody-dependent enhancement |
| Q38935048 | Epidemiological and molecular features of dengue virus type-1 in New Caledonia, South Pacific, 2001-2013. |
| Q21131163 | Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections |
| Q35866928 | Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics |
| Q40243027 | Episode of coexisting infections with multiple dengue virus serotypes in central Karnataka, India |
| Q27485025 | Epitope Determinants of a Chimpanzee Dengue Virus Type 4 (DENV-4)-Neutralizing Antibody and Protection against DENV-4 Challenge in Mice and Rhesus Monkeys by Passively Transferred Humanized Antibody |
| Q40297371 | Estimated prevalence of dengue viremia in Puerto Rican blood donations, 1995 through 2010. |
| Q40081496 | Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies |
| Q39157043 | Evaluation of molecular strategies to develop a live dengue vaccine |
| Q34522384 | Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. |
| Q40552138 | Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice |
| Q33609685 | Evasion of the human innate immune system by dengue virus |
| Q40373757 | Evolution, dispersal and replacement of American genotype dengue type 2 viruses in India (1956-2005): selection pressure and molecular clock analyses |
| Q27469648 | Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses |
| Q45751292 | Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections |
| Q101038705 | Experimental adaptation of dengue virus 1 to Aedes albopictus mosquitoes by in vivo selection |
| Q54259302 | Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections. |
| Q56378326 | Experimental infection of human volunteers |
| Q41566459 | Factors in the past and future evolution of the arborviruses |
| Q26864533 | Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus |
| Q40367378 | Fever, emesis, abdominal pain, and pancytopenia in a 16-year-old girl |
| Q40053540 | First identification of Culex flavivirus (Flaviviridae) in Brazil |
| Q40276744 | Flaviviruses |
| Q38045616 | Flaviviruses and their antigenic structure |
| Q30857727 | Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus |
| Q56793078 | Flaviviruses: Dengue |
| Q64124634 | Force-of-infection and True Infection Rate of Dengue in Singapore - its implication on dengue control and management |
| Q56353070 | Forecasting the effectiveness of indoor residual spraying for reducing dengue burden |
| Q40099142 | Functional properties of DENV EDIII‑reactive antibodies in human DENV‑1‑infected sera and rabbit antiserum to EDIII. |
| Q40493256 | G+C content differs in conserved and variable amino acid residues of flaviviruses and other evolutionary groups |
| Q36730637 | Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains |
| Q34104330 | Genetic and phenotypic characterization of sylvatic dengue virus type 4 strains |
| Q27486073 | Genetic determinants of dengue type 4 virus neurovirulence for mice |
| Q27472563 | Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. |
| Q27682470 | Genome-wide analyses reveal a highly conserved Dengue virus envelope peptide which is critical for virus viability and antigenic in humans |
| Q38937323 | Genotypic characterization of dengue virus strains circulating during 2007-2009 in New Delhi |
| Q26782367 | Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine |
| Q40569492 | HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. |
| Q36539043 | HLA-A*0201-restricted CD8+ T-cell epitopes identified in dengue viruses |
| Q36933241 | HLA-B∗44 Is Associated with Dengue Severity Caused by DENV-3 in a Brazilian Population |
| Q27980556 | Heterologous Protection against Asian Zika Virus Challenge in Rhesus Macaques |
| Q24705225 | Heterologous protection against Asian Zika virus challenge in rhesus macaques |
| Q40741031 | Heterologous resistance to superinfection by louping ill virus persistently infected cell cultures |
| Q34763787 | Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic |
| Q39799030 | High rate of unrecognized dengue virus infection in parts of the rainforest region of Nigeria. |
| Q37336440 | High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection |
| Q37535876 | Highly Divergent Dengue Virus Type 2 in Traveler Returning from Borneo to Australia |
| Q29994534 | Historical Perspectives on Flavivirus Research |
| Q38381598 | Homotypic Dengue Virus Reinfections in Nicaraguan Children |
| Q40070662 | How Did the Dengue Fever Outbreak Progress in Yoyogi Park, Tokyo, in 2014?-Evaluation Based on a Mathematical Model |
| Q91435707 | How Modelling Can Enhance the Analysis of Imperfect Epidemic Data |
| Q26314609 | Human antibody response to dengue virus: implications for dengue vaccine design |
| Q37735002 | Human immune responses to dengue virus infection: lessons learned from prospective cohort studies |
| Q33764959 | Human to mosquito transmission of dengue viruses |
| Q92922226 | Humanized Mice in Dengue Research: A Comparison with Other Mouse Models |
| Q27488243 | Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens |
| Q78177475 | Identification of Zika virus in immature phases of Aedes aegypti and Aedes albopictus: a surveillance strategy for outbreak anticipation. |
| Q38125045 | Identifying protective dengue vaccines: guide to mastering an empirical process |
| Q47551925 | Immune Response to Dengue and Zika |
| Q51336680 | Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development. |
| Q33924674 | Immune correlates for dengue vaccine development |
| Q37827145 | Immune response to dengue virus and prospects for a vaccine |
| Q41929349 | Immune status alters the probability of apparent illness due to dengue virus infection: Evidence from a pooled analysis across multiple cohort and cluster studies. |
| Q37901360 | Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms |
| Q27486490 | Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis |
| Q39243877 | Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge |
| Q27483531 | Immunological enhancement and the pathogenesis of dengue haemorrhagic fever |
| Q35613349 | Immunology and immunopathogenesis of dengue disease |
| Q39410861 | Immunopathogenesis Versus Protection in Dengue Virus Infections |
| Q33784757 | Impact of dengue/dengue hemorrhagic fever on the developing world |
| Q92937581 | Impact of population displacement and forced movements on the transmission and outbreaks of Aedes-borne viral diseases: Dengue as a model |
| Q38157106 | Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques |
| Q92024402 | Impacts of Zika emergence in Latin America on endemic dengue transmission |
| Q54306802 | Imunocompetent mice model for dengue virus infection. |
| Q30250977 | In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination |
| Q28550030 | Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru |
| Q34281507 | Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey |
| Q27485321 | Infection-Enhancing and -Neutralizing Activities of Mouse Monoclonal Antibodies against Dengue Type 2 and 4 Viruses Are Controlled by Complement Levels |
| Q36363799 | Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance |
| Q34144495 | Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers |
| Q30833371 | Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation |
| Q92633439 | Influence of chemokines on the endothelial permeability and cellular transmigration during dengue |
| Q40277666 | Influence of evolutionary events on the Indian subcontinent on the phylogeography of dengue type 3 and 4 viruses |
| Q47558169 | Innovative and new approaches to laboratory diagnosis of Zika and dengue: a meeting report |
| Q90462841 | Insights from direct studies on human dengue infections |
| Q34634859 | Interaction and inhibition of dengue envelope glycoprotein with mammalian receptor DC-sign, an in-silico approach |
| Q37062703 | Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity |
| Q40318917 | Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate |
| Q43031391 | Interference between bunyaviruses in Aedes triseriatus mosquitoes |
| Q34754885 | Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection |
| Q33597509 | Isolation of dengue virus from the upper respiratory tract of four patients with dengue fever. |
| Q27469274 | Isolation of three strains of type 1 dengue virus from a local outbreak of the disease in Malaya |
| Q30395396 | Issues related to recent dengue vaccine development |
| Q38618056 | Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates? |
| Q110742666 | Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation |
| Q42991074 | Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology |
| Q37336555 | Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge |
| Q35133990 | Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection |
| Q24289053 | Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes |
| Q66679636 | Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand |
| Q63246361 | Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model |
| Q30392050 | Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients |
| Q27486907 | Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity |
| Q39329367 | Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement |
| Q23032973 | Mechanism and significance of cell type-dependent neutralization of flaviviruses |
| Q27676931 | Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody |
| Q34306877 | Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop |
| Q34088956 | Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive |
| Q28742358 | Microevolution and virulence of dengue viruses |
| Q92717077 | Micronutrients, Immunological Parameters, and Dengue Virus Infection in Coastal Ecuador: A Nested Case-Control Study in an Infectious Disease Surveillance Program |
| Q35009344 | Minimal within-host dengue models highlight the specific roles of the immune response in primary and secondary dengue infections |
| Q95297212 | Modelling the impact of antibody-dependent enhancement on disease severity of Zika virus and dengue virus sequential and co-infection |
| Q35082837 | Models of the impact of dengue vaccines: a review of current research and potential approaches |
| Q66679750 | Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus |
| Q35873247 | Molecular characterization of midgut microbiota of Aedes albopictus and Aedes aegypti from Arunachal Pradesh, India |
| Q38989101 | Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection |
| Q40624155 | Molecular epidemiology of dengue viruses in Brazil |
| Q47548302 | Molecular epidemiology of dengue viruses in three provinces of Lao PDR, 2006-2010. |
| Q36718992 | Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease |
| Q40558983 | Molecular typing of dengue virus type 2 in Brazil |
| Q27480391 | Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge |
| Q24684689 | Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention |
| Q64259781 | Mouse Models of Heterologous Flavivirus Immunity: A Role for Cross-Reactive T Cells |
| Q37213365 | Mouse models of dengue virus infection and disease |
| Q24276139 | Mouse models of dengue virus infection for vaccine testing |
| Q33796710 | Mucocutaneous manifestations of Dengue fever |
| Q27491299 | Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses |
| Q35147237 | Natural attenuation of dengue virus type-2 after a series of island outbreaks: a retrospective phylogenetic study of events in the South Pacific three decades ago. |
| Q40393004 | Natural vertical transmission by Stegomyia albopicta as dengue vector in Brazil |
| Q35034151 | Natural, persistent oscillations in a spatial multi-strain disease system with application to dengue |
| Q29618172 | Neutralization and antibody-dependent enhancement of dengue viruses |
| Q39265055 | Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies |
| Q27490987 | Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient |
| Q24652746 | Neutralizing antibodies after infection with dengue 1 virus |
| Q36498207 | Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort |
| Q38646923 | New insights into the immunopathology and control of dengue virus infection |
| Q27469339 | New mouse model for dengue virus vaccine testing |
| Q35491639 | Next-generation dengue vaccines: novel strategies currently under development |
| Q38861029 | Novel concept on antiviral strategies to dengue. |
| Q40791252 | Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses |
| Q98777432 | Nutritional status impacts dengue virus infection in mice |
| Q24736978 | Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion |
| Q39279398 | Outbreak of febrile illness due to dengue virus type 3 in Calcutta during 1983. |
| Q30409659 | Pandemic dengue in Caribbean countries and the southern United States--past, present and potential problems |
| Q40216797 | Partial cross-enhancement in models for dengue epidemiology. |
| Q35613346 | Pathogenesis and pathophysiology of yellow fever |
| Q26766198 | Pathogenesis of Dengue: Dawn of a New Era |
| Q27860978 | Pathogenesis of dengue: challenges to molecular biology |
| Q35539426 | Pathogenesis of rashes in virus diseases |
| Q64359404 | Peripheral follicular helper T cells in acute viral diseases: a perspective on dengue |
| Q27490989 | Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers |
| Q27487377 | Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity |
| Q35913916 | Phylodynamics of Enterovirus A71-Associated Hand, Foot, and Mouth Disease in Viet Nam. |
| Q34548508 | Physicochemical property consensus sequences for functional analysis, design of multivalent antigens and targeted antivirals |
| Q37683785 | Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand |
| Q40268140 | Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes |
| Q40592244 | Population structure of Aedes albopictus from La Réunion Island (Indian Ocean) with respect to susceptibility to a dengue virus |
| Q98160120 | Possible Drivers of the 2019 Dengue Outbreak in Bangladesh: The Need for a Robust Community-Level Surveillance System |
| Q35152094 | Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement |
| Q36718596 | Potential of ancestral sylvatic dengue-2 viruses to re-emerge |
| Q34080726 | Potential opportunities and perils of imperfect dengue vaccines. |
| Q37609595 | Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses |
| Q45324741 | Preconceptual Zika virus asymptomatic infection protects against secondary prenatal infection. |
| Q31032937 | Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand |
| Q27485489 | Primary and Secondary Infections of Macaca fascicularis Monkeys with Asian and American Genotypes of Dengue Virus 2 |
| Q40372399 | ProactiveVector control strategies and improved monitoring and evaluation practices for dengue prevention |
| Q35645556 | Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. |
| Q35009119 | Progress towards a dengue vaccine |
| Q29619608 | Prospects for a dengue virus vaccine |
| Q40783257 | Protection against Japanese encephalitis by inactivated vaccines |
| Q39434858 | Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells |
| Q38731663 | Protective and immunological behavior of chimeric yellow fever dengue vaccine |
| Q56788369 | Quantifying the added value of climate information in a spatio-temporal dengue model |
| Q40822336 | Quantity of dengue virus required to infect rhesus monkeys |
| Q91999115 | Rapid Neutralization Testing System for Zika Virus Based on an Enzyme-Linked Immunospot Assay |
| Q40369470 | Rapid structural characterization of human antibody-antigen complexes through experimentally validated computational docking |
| Q27477646 | Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis |
| Q35728621 | Recent advancement in flavivirus vaccine development |
| Q92859173 | Recent advances in understanding dengue |
| Q38158407 | Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure |
| Q41012504 | Recent work on dengue fever. |
| Q40646852 | Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones |
| Q27485981 | Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones |
| Q27469664 | Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates |
| Q40293933 | Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice |
| Q40706732 | Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice |
| Q40439273 | Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines |
| Q27469474 | Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys |
| Q30145646 | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico |
| Q37109553 | Reduced risk of disease during postsecondary dengue virus infections |
| Q34344625 | Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever. |
| Q27486395 | Relationship between Transmission Intensity and Incidence of Dengue Hemorrhagic Fever in Thailand |
| Q36060983 | Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient Mice |
| Q40593098 | Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein |
| Q36846970 | Research on dengue and dengue-like illness in East Asia and the Western Pacific during the First Half of the 20th century |
| Q27022905 | Return of epidemic dengue in the United States: implications for the public health practitioner |
| Q36066463 | Revealing the microscale spatial signature of dengue transmission and immunity in an urban population |
| Q34640272 | Review article: Research on dengue during World War II revisited |
| Q34154128 | Review of dengue virus and the development of a vaccine |
| Q36181531 | Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults |
| Q26860307 | Role of microparticles in dengue virus infection and its impact on medical intervention strategies |
| Q39468688 | Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study |
| Q36382589 | Sculpting humoral immunity through dengue vaccination to enhance protective immunity |
| Q38087545 | Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection |
| Q33303314 | Selection of phage-displayed human antibody fragments on Dengue virus particles captured by a monoclonal antibody: application to the four serotypes |
| Q33463029 | Sensitive detection of hantaviruses by biotin-streptavidin enhanced immunoassays based on bank vole monoclonal antibodies |
| Q34978832 | Sequence of the dengue virus type 2 (strain PR-159) NS1 gene and comparison with its vaccine derivative |
| Q35211928 | Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010. |
| Q40204952 | Sequential episodes of dengue--Puerto Rico, 2005-2010. |
| Q98164941 | Sequential immunization induces strong and broad immunity against all four dengue virus serotypes |
| Q59351814 | Sera of patients with systemic lupus erythematosus cross-neutralizes dengue viruses |
| Q40992163 | Serial propagation of types 1, 2, 3 and 4 dengue virus in HeLa cells with concomitant cytopathic effect |
| Q33664425 | Serological evidence for transmission of multiple dengue virus serotypes in Papua New Guinea and West Papua prior to 1963 |
| Q66678780 | Serological inference of past primary and secondary dengue infection: implications for vaccination |
| Q34496118 | Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico |
| Q39097390 | Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2. |
| Q36226190 | Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes. |
| Q33709817 | Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control |
| Q24701784 | Sindbis virus interferes with dengue 4 virus replication and its potential transmission by Aedes albopictus |
| Q33906261 | Space-time analysis of hospitalised dengue patients in rural Thailand reveals important temporal intervals in the pattern of dengue virus transmission |
| Q28741831 | Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus |
| Q34005264 | Statistical inference for multi-pathogen systems |
| Q27678419 | Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity |
| Q27674417 | Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope |
| Q27675965 | Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus |
| Q27488378 | Structure-based discovery of dengue virus protease inhibitors |
| Q27487448 | Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes |
| Q40070804 | Superinfection interference between dengue-2 and dengue-4 viruses in Aedes aegypti mosquitoes |
| Q45718676 | Survey of knowledge and problems in field of arthropod-borne virus infections |
| Q40522012 | Sustained transmission of dengue virus type 1 in the Pacific due to repeated introductions of different Asian strains |
| Q34952330 | Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year |
| Q27901943 | THE EMERGENCE OF ARTHROPOD-BORNE VIRAL DISEASES: A GLOBAL PROSPECTIVE ON DENGUE, CHIKUNGUNYA AND ZIKA FEVERS |
| Q27486963 | TICK-BORNE VIRUSES. A REVIEW OF AN ARTHROPOD-BORNE VIRUS PROBLEM OF GROWING IMPORTANCE IN THE TROPICS |
| Q36118259 | Targeted mutagenesis as a rational approach to dengue virus vaccine development |
| Q39122461 | Temporal trends and regional variability of 2001-2002 multiwave DENV-3 epidemic in Havana City: did Hurricane Michelle contribute to its severity? |
| Q33222362 | Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen |
| Q103781582 | The Absence of Yellow Fever in Asia: History, Hypotheses, Vector Dispersal, Possibility of YF in Asia, and Other Enigmas |
| Q26700056 | The Cellular Bases of Antibody Responses during Dengue Virus Infection |
| Q37363582 | The Chosen Few: Only a Subset of Memory B Cells Responds to Secondary Dengue Virus Infections |
| Q61053702 | The Decline of Dengue in the Americas in 2017: Discussion of Multiple Hypotheses |
| Q94590354 | The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines |
| Q27487741 | The First Major Outbreak of Dengue Hemorrhagic Fever in Delhi, India |
| Q102073071 | The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study |
| Q27490855 | The Incidence, Characteristics, and Presentation of Dengue Virus Infections during Infancy |
| Q39119333 | The Influence of Spatial Configuration of Residential Area and Vector Populations on Dengue Incidence Patterns in an Individual-Level Transmission Model |
| Q90972676 | The Interplay between Dengue Virus and the Human Innate Immune System: A Game of Hide and Seek |
| Q27469278 | The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic |
| Q92637321 | The Removal of Subterranean Stormwater Drain Sumps as Mosquito Breeding Sites in Darwin, Australia |
| Q40820979 | The absence of dengue virus in the skin lesions of dengue fever |
| Q40397430 | The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model |
| Q35822483 | The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? |
| Q28250383 | The complexity of antibody-dependent enhancement of dengue virus infection |
| Q42987133 | The dengue human challenge model: has the time come to accept this challenge? |
| Q24616798 | The dengue viruses |
| Q41009225 | The distribution of antibodies to Japanese Encephalitis, dengue, and yellow fever viruses in five rural communities in Malaya |
| Q59360735 | The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy |
| Q40429074 | The dynamics of dengue virus serotype 3 introduction and dispersion in the state of Bahia, Brazil |
| Q40265821 | The effect of antibody-dependent enhancement, cross immunity, and vector population on the dynamics of dengue fever |
| Q38579291 | The emergence of dengue in Bangladesh: epidemiology, challenges and future disease risk |
| Q37176335 | The exanthem of Ross River virus infection: histology, location of virus antigen and nature of inflammatory infiltrate |
| Q40312562 | The first dominant co-circulation of both dengue and chikungunya viruses during the post-monsoon period of 2010 in Delhi, India. |
| Q34903764 | The history and evolution of human dengue emergence |
| Q34992520 | The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes |
| Q35033974 | The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study |
| Q36132065 | The impact of transgenic mosquitoes on dengue virulence to humans and mosquitoes |
| Q40695456 | The influence of antibody levels in dengue diagnosis by polymerase chain reaction |
| Q40109446 | The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model |
| Q40550255 | The potential of virulent Wolbachia to modulate disease transmission by insects |
| Q40817405 | The quantitative kinetic study of dengue viral antigen by flow cytometry. I. An in vitro study |
| Q33954195 | The role of climate variability and change in the transmission dynamics and geographic distribution of dengue |
| Q40568715 | The seasonal pattern of dengue in endemic areas: mathematical models of mechanisms |
| Q27681306 | The structural basis for serotype-specific neutralization of dengue virus by a human antibody |
| Q37135489 | The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. |
| Q35069160 | The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein |
| Q38149195 | Therapeutic antibodies as a treatment option for dengue fever |
| Q34607919 | Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. |
| Q37350360 | Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses |
| Q40956994 | Three-year study of mosquito-borne haemorrhagic fever in Calcutta |
| Q33854218 | Time-varying, serotype-specific force of infection of dengue virus |
| Q36112987 | Total and Envelope Protein-Specific Antibody-Secreting Cell Response in Pediatric Dengue Is Highly Modulated by Age and Subsequent Infections |
| Q35143285 | Traditional and novel approaches to flavivirus vaccines |
| Q92119078 | Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection |
| Q33573351 | Transmission of West Nile virus by Culex quinquefasciatus say infected with Culex Flavivirus Izabal |
| Q55333503 | Transmission-clearance trade-offs indicate that dengue virulence evolution depends on epidemiological context. |
| Q93029309 | Travelling arboviruses: A historical perspective |
| Q38032553 | Treatment of dengue fever |
| Q38641452 | Trials and Tribulations on the Path to Developing a Dengue Vaccine |
| Q38540058 | Trials and tribulations on the path to developing a dengue vaccine |
| Q91741475 | Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design |
| Q54226258 | Understanding dengue virus evolution to support epidemic surveillance and counter-measure development. |
| Q27011587 | Understanding the dengue viruses and progress towards their control |
| Q43034442 | Unique challenges faced by the clinical evaluation of dengue vaccines |
| Q101472278 | Use of Animal Models in Studying Roles of Antibodies and Their Secretion Cells in Dengue Vaccine Development |
| Q91153816 | Using Multiple Scale Spatio-Temporal Patterns for Validating Spatially Explicit Agent-Based Models |
| Q56417600 | Using paired serology and surveillance data to quantify dengue transmission and control during a large outbreak in Fiji |
| Q58388838 | Using paired serology and surveillance data to quantify dengue transmission and control during a large outbreak in Fiji |
| Q38015980 | Using recombinant DNA technology for the development of live-attenuated dengue vaccines. |
| Q34238916 | Utility, limitations, and future of non-human primates for dengue research and vaccine development |
| Q38620005 | Vaccination Against Dengue: Challenges and Current Developments |
| Q37184768 | Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles |
| Q38766614 | Vaccine Development as a Means to Control Dengue Virus Pathogenesis: Do We Know Enough? |
| Q52584608 | Variation in Wolbachia effects on Aedes mosquitoes as a determinant of invasiveness and vectorial capacity. |
| Q31137783 | Vertical Transmission of Dengue Virus in the Peripartum Period and Viral Kinetics in Newborns and Breast Milk: New Data |
| Q33859643 | Vertical transmission of dengue virus in Aedes aegypti collected in Puerto Iguazú, Misiones, Argentina |
| Q38638220 | Viral Interference and Persistence in Mosquito-Borne Flaviviruses |
| Q33761030 | Viral and epidemiological determinants of the invasion dynamics of novel dengue genotypes |
| Q40233684 | Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination |
| Q39663777 | Viruses Associated with Epidemic Hemorrhagic Fevers of the Philippines and Thailand |
| Q91867669 | When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection? |
| Q38157725 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine |
| Q40047872 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner |
| Q38947779 | Within-host viral dynamics of dengue serotype 1 infection |
| Q34722636 | Worldwide spread of Dengue virus type 1. |
| Q27490528 | Yellow Fever Virus Exhibits Slower Evolutionary Dynamics than Dengue Virus |
| Q36238729 | Yellow fever vaccine |
| Q47549681 | Zika Virus Fatally Infects Wild Type Neonatal Mice and Replicates in Central Nervous System |
| Q92441397 | Zika Virus Infection in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and Possible Implication for Cross-Reactivity and Cross-Protection |
| Q38969772 | Zika Virus: Immunity and Vaccine Development |
| Q40457487 | [Liver involvement in patients with dengue hemorrhagic fever: a rare phenomenon?]. |
Search more.